

Patent Claims

1. Nucleic acid, characterised in that it codes for the non-selective cation channel OTRPC4 or for a fragment, a functional variant, an allelic variant or
5 a subunit, or variants of said nucleic acid on the basis of the degenerative code or a nucleic acid which is able to hybridise with said nucleic acid.
2. Nucleic acid according to claim 1, characterised in that it is RNA.
- 10 3. Nucleic acid according to claim 1, characterised in that it is DNA.
4. Nucleic acid according to one of claims 1 or 3, characterised in that it contains 5' or 3' or 5' and 3' untranslated regions.
- 15 5. Nucleic acid according to one of claims 1 to 4, characterised in that it codes for a fragment of the non-selective cation channel OTRPC4.
- 6 Nucleic acid according to one of claims 1 to 5, characterised in that it codes for a functional variant of the non-selective cation channel OTRPC4.
- 20 7. Nucleic acid according to one of claims 1 to 6, characterised in that it codes for an allelic variant of the non-selective cation channel OTRPC4.
8. Nucleic acid according to one of claims 1 to 7, characterised in that it codes
25 for variants of nucleic acid on the basis of the degenerative code.
9. Nucleic acid, characterised in that it is capable of hybridising with a nucleic acid according to one of claims 1 to 8 under stringent conditions.
- 30 10. Nucleic acid according to one of claims 1 to 9, characterised in that the said non-selective cation channel OTRPC4 is a mammalian cation channel.

11. Nucleic acid according to one of claims 1 to 10, characterised in that the said non-selective cation channel OTRPC4 is murine.

12. Nucleic acid according to one of claims 1 to 11, characterised in that the said
5 non-selective cation channel OTRPC4 is human.

13. Nucleic acid, characterised in that it contains the sequence

CTCTACCGCCTACTACCAGCCGCTGGAGGGCACAATGGCGGATTCCAGCGAA
10 GGCCCCCGCGCGGGGCCCCGGGGAGGTGGCTGAGCTCCCCGGGGATGAGAGTGG
CACCCCAGGTGGGGAGGCTTTTCCTCTCTCCTCCCTGGCCAATCTGTTTGAGGG
GGAGGATGGCTCCCTTTCGCCCTACCGGCTGATGCCAGTCGCCCTGCTGGCCC
AGGCGATGGGCGACCAAATCTGCGCATGAAGTTCCAGGGCGCCTTCCGCAAGG
GGGTGCCCAACCCCATCGATCTGCTGGAGTCCACCCTATATGAGTCCTCGGTGG
15 TGCCTGGGCCCAAGAAAGCACCCATGGACTCACTGTTTGACTACGGCACCTATC
GTCACCACTCCAGTGACAACAAGAGGTGGAGGAAGAAGATCATAGAGAAGCA
GCCGCAGAGCCCCAAAGCCCCTGCCCCTCAGCCGCCCCCATCCTCAAAGTCTT
CAACCGGCCTATCCTCTTTGACATCGTGTCCCGGGGCTCCACTGCTGACCTGGA
CGGGCTGCTCCCATTTCTTGCTGACCCACAAGAAACGCCTAACTGATGAGGAGTT
20 TCGAGAGCCATCTACGGGGAAGACCTGCCTGCCCAAGGCCTTGCTGAACCTGA
GCAATGGCCGCAACGACACCATCCCTGTGCTGCTGGACATCGCGGAGCGCACC
GGCAACATGCGGGAGTTCATTAACCTCGCCCTTCCGTGACATCTACTATCGAGGT
CAGACAGCCCTGCACATCGCCATTGAGCGTCGCTGCAAACACTACGTGGAACCT
TCTCGTGGCCCAGGGAGCTGATGTCCAAGCCAGGCCCGTGGGCGCTTCTTCCA
25 GCCCAAGGATGAGGGGGGCTACTTCTACTTTGGGGAGCTGCCCCTGTGCTGGC
TGCCTGCACCAACCAGCCCCACATTGTCAACTACCTGACGGAGAACCCCCACA
AGAAGGCGGACATGCGGCGCCAGGACTCGCGAGGCAACACAGTGCTGCATGC
GCTGGTGGCCATTGCTGACAACACCCGTGAGAACACCAAGTTTGTACCAAGA
TGACGACCTGCTGCTGCTCAAGTGTGCCCCGCTCTTCCCCGACAGCAACCTGG
30 AGGCCGTGCTCAACAACGACGGCCTCTCGCCCCTCATGATGGCTGCCAAGACG
GGCAAGATTGGGATCTTTCAGCACATCATCCGGCGGGAGGTGACGGATGAGGA
CACACGGCACCTGTCCCGCAAGTTCAAGGACTGGGCCTATGGGCCAGTGATTTC
CTCGCTTTATGACCTCTCCTCCCTGGACACGTGTGGGGAAGAGGCCTCCGTGCT
GGAGATCCTGGTGTACAACAGCAAGATTGAGAACCGCCACGAGATGCTGGCTG

TGGAGCCCATCAATGAACTGCTGCGGGACAAGTGGCGCAAGTTCGGGGCCGTC
TCCTTCTACATCAACGTGGTCTCCTACCTGTGTGCCATGGTCATCTTCACTCTCA
CCGCCTACTACCAGCCGCTGGAGGGCACACCGCCGTACCCTTACCGCACCACG
GTGGACTACCTGCGGCTGGCTGGCGAGGTCATTACGCTCTTCACTGGGGTCCTG
5 TTCTTCTTCACCAACATCAAAGACTTGTTTCATGAAGAAATGCCCTGGAGTGAAT
TCTCTCTTCATTGATGGCTCCTTCCAGCTGCTCTACTTCATCTACTCTGTCTCTGGT
GATCGTCTCAGCAGCCCTCTACCTGGCAGGGATCGAGGCCTACCTGGCCGTGAT
GGTCTTTGCCCTGGTCCTGGGCTGGATGAATGCCCTTTACTTCACCCGTGGGCT
GAAGCTGACGGGGACCTATAGCATCATGATCCAGAAGATTCTCTTCAAGGACC
10 TTTTCCGATTCTGCTCGTCTACTTGCTCTTCATGATCGGCTACGCTTCAGCCCT
GGTCTCCCTCCTGAACCCGTGTGCCAACATGAAGGTGTGCAATGAGGACCAGA
CCAACTGCACAGTGCCCACTTACCCCTCGTGCCGTGACAGCGAGACCTTCAGCA
CCTTCCTCCTGGACCTGTTTAAGCTGACCATCGGCATGGGCGACCTGGAGATGC
TGAGCAGCACCAAGTACCCCGTGGTCTTCATCATCCTGCTGGTGACCTACATCA
15 TCCTCACCTTTGTGCTGCTCCTCAACATGCTCATTGCCCTCATGGGCGAGACAG
TGGGCCAGGTCTCCAAGGAGAGCAAGCACATCTGGAAGCTGCAGTGGGCCACC
ACCATCCTGGACATTGAGCGCTCCTTCCCCGTATTCCTGAGGAAGGCCTTCCGC
TCTGGGGAGATGGTCACCGTGGGCAAGAGCTCGGACGGCACTCCTGACCGCAG
GTGGTGCTTCAGGGTGGATGAGGTGAACTGGTCTCACTGGAACCAGAACTTGG
20 GCATCATCAACGAGGACCCGGGCAAGAATGAGACCTACCAGTATTATGGCTTC
TCGCATACCGTGGGCCCGCCTCCGCAGGGATCGCTGGTCTCGGTGGTACCCCGC
GTGGTGGAACCTGAACAAGAACTCGAACCCGGACGAGGTGGTGGTGCCTCTGGA
CAGCATGGGGAACCCCGCTGCGATGGCCACCAGCAGGGTTACCCCGCAAGT
GGAGGACTGAGGACGCCCCGCTCTAGGGACTGCAGCCCAGCCCCAGCTTCTCT
25 GCCCCACTCATTTCTAGTCCAGCCGCATTTACAGCAGTGCCTTCTGGGGTGTCCCC
CCACACCCTGCTTTGGCCCCAGAGGCGAGGGACCAGTGGAGGTGCCAGGGAGG
CCCCAGGACCCTGTGGTCCCCTGGCTCTGCCTCCCCACCCTGGGGTGGGGGCTC
CCGGCCACCTGTCTTGCTCCTATGGAGTCACATAAGCCAACGCCAGAGCCCCTC
CACCTCAGGCCCCAGCCCCTGCCTCTCCATTATTTATTTGCTCTGCTCTCAGGAA
30 GCGACGTGACCCCTGCCCCAGCTGGAACCTGGCAGAGGCCTTAGGACCCCGTT
CCAAGTGCACTGCCCGGCCAAGCCCCAGCCTCAGCCTGCGCCTGAGCTGCATG
CGCCACCATTTTTGGCAGCGTGGCAGCTTTGCAAGGGGCTGGGGCCCTCGGGCGT
GGGGCCATGCCTTCTGTGTGTTCTGTAGTGTCTGGGATTTGCCGGTGCTCAATA
AATGTTTATTTCATTGACGGTGAAAAAAAAAAAAAAAAAAAAA

or a partial sequence thereof, a nucleic acid which is capable of hybridising with said sequence under stringent conditions, an allelic variant or a functional variant of said sequence or a variant of nucleic acid on the basis of the degenerative code.

- 5 14. Nucleic acid, characterised in that it has the sequence
- CTCTACCGCCTACTACCAGCCGCTGGAGGGCACAATGGCGGATTCCAGCGAA
GGCCCCCGCGCGGGGCCCCGGGGAGGTGGCTGAGCTCCCCGGGGATGAGAGTGG
CACCCCAGGTGGGGAGGCTTTTCCTCTCTCCTCCCTGGCCAATCTGTTTGAGGG
GGAGGATGGCTCCCTTTGCCCCTACCGGCTGATGCCAGTCGCCCTGCTGGCCC
10 AGGCGATGGGCGACCAAATCTGCGCATGAAGTTCCAGGGCGCCTTCCGCAAGG
GGGTGCCCAACCCCATCGATCTGCTGGAGTCCACCCTATATGAGTCCTCGGTGG
TGCCTGGGCCCCAAGAAAGCACCCATGGACTCACTGTTTGACTACGGCACCTATC
GTCACCACTCCAGTGACAACAAGAGGTGGAGGAAGAAGATCATAGAGAAGCA
GCCGCAGAGCCCCAAAGCCCCTGCCCCTCAGCCGCCCCCATCCTCAAAGTCTT
15 CAACCGGCCTATCCTCTTTGACATCGTGTCCCGGGGCTCCACTGCTGACCTGGA
CGGGCTGCTCCCAATTCTTGCTGACCCACAAGAAACGCCTAACTGATGAGGAGTT
TCGAGAGCCATCTACGGGGAAGACCTGCCTGCCCAAGGCCTTGCTGAACCTGA
GCAATGGCCGCAACGACACCATCCCTGTGCTGCTGGACATCGCGGAGCGCACC
GGCAACATGCGGGAGTTCATTAACCTCGCCCTTCCGTGACATCTACTATCGAGGT
20 CAGACAGCCCTGCACATCGCCATTGAGCGTCGCTGCAAACACTACGTGGAAC
TCTCGTGGCCCAGGGAGCTGATGTCCACGCCCAGGCCCGTGGGCGCTTCTTCCA
GCCCAAGGATGAGGGGGGCTACTTCTACTTTGGGGAGCTGCCCCTGTCGCTGGC
TGCCTGCACCAACCAGCCCCACATTGTCAACTACCTGACGGAGAACCCCCACA
AGAAGGCGGACATGCGGCGCCAGGACTCGCGAGGCAACACAGTGCTGCATGC
25 GCTGGTGGCCATTGCTGACAACACCCGTGAGAACACCAAGTTTGTACCAAGA
TGACGACCTGCTGCTGCTCAAGTGTGCCCCGCTCTTCCCCGACAGCAACCTGG
AGGCCGTGCTCAACAACGACGGCCTCTCGCCCCTCATGATGGCTGCCAAGACG
GGCAAGATTGGGATCTTTCAGCACATCATCCGGCGGGAGGTGACGGATGAGGA
CACACGGCACCTGTCCCGCAAGTTCAAGGACTGGGCCTATGGGCCAGTGATTTC
30 CTCGCTTTATGACCTCTCCTCCCTGGACACGTGTGGGGAAGAGGCCTCCGTGCT
GGAGATCCTGGTGTACAACAGCAAGATTGAGAACCGCCACGAGATGCTGGCTG
TGGAGCCCATCAATGAACTGCTGCGGGACAAGTGGCGCAAGTTCGGGGCCGTC
TCCTTCTACATCAACGTGGTCTCCTACCTGTGTGCCATGGTCATCTTCACTCTCA
CCGCCTACTACCAGCCGCTGGAGGGCACACCGCCGTACCCTTACCGCACCACG

GTGGACTACCTGCGGCTGGCTGGCGAGGTCATTACGCTCTTCACTGGGGTCCTG
TTCTTCTTCACCAACATCAAAGACTTGTTTCATGAAGAAATGCCCTGGAGTGAAT
TCTCTCTTCATTGATGGCTCCTTCCAGCTGCTCTACTTCATCTACTCTGTCTGGT
GATCGTCTCAGCAGCCCTCTACCTGGCAGGGATCGAGGCCTACCTGGCCGTGAT
5 GGTCTTTGCCCTGGTCCTGGGCTGGATGAATGCCCTTTACTTCACCCGTGGGCT
GAAGCTGACGGGGACCTATAGCATCATGATCCAGAAGATTCTCTTCAAGGACC
TTTTCCGATTCTGCTCGTCTACTTGCTCTTCATGATCGGCTACGCTTCAGCCCT
GGTCTCCCTCCTGAACCCGTGTGCCAACATGAAGGTGTGCAATGAGGACCAGA
CCAACTGCACAGTGCCCACTTACCCCTCGTGCCGTGACAGCGAGACCTTCAGCA
10 CCTTCCTCCTGGACCTGTTTAAGCTGACCATCGGCATGGGCGACCTGGAGATGC
TGAGCAGCACCAAGTACCCCGTGGTCTTCATCATCCTGCTGGTGACCTACATCA
TCCTCACCTTTGTGCTGCTCCTCAACATGCTCATTGCCCTCATGGGCGAGACAG
TGGGCCAGGTCTCCAAGGAGAGCAAGCACATCTGGAAGCTGCAGTGGGCCACC
ACCATCCTGGACATTGAGCGCTCCTTCCCGTATTCCTGAGGAAGGCCTTCCGC
15 TCTGGGGAGATGGTCACCGTGGGCAAGAGCTCGGACGGCACTCCTGACCGCAG
GTGGTGCTTCAGGGTGGATGAGGTGAACTGGTCTCACTGGAACCAGAACTTGG
GCATCATCAACGAGGACCCGGGCAAGAATGAGACCTACCAGTATTATGGCTTC
TCGCATACCGTGGGCCCGCCTCCGCAGGGATCGCTGGTCCCTCGGTGGTACCCCGC
GTGGTGGAACCTGAACAAGAACTCGAACCCGGACGAGGTGGTGGTGCCTCTGGA
20 CAGCATGGGGAACCCCGCTGCGATGGCCACCAGCAGGGTTACCCCGCAAGT
GGAGGACTGAGGACGCCCCGCTCTAGGGACTGCAGCCCAGCCCCAGCTTCTCT
GCCCCACTCATTTCTAGTCCAGCCGCATTTAGCAGTGCCTTCTGGGGTGTCCCC
CCACACCCTGCTTTGGCCCCAGAGGCGAGGGACCAGTGGAGGTGCCAGGGAGG
CCCCAGGACCCTGTGGTCCCCTGGCTCTGCCTCCCCACCCTGGGGTGGGGGCTC
25 CCGGCCACCTGTCTTGCTCCTATGGAGTCACATAAGCCAACGCCAGAGCCCCTC
CACCTCAGGCCCCAGCCCCTGCCTCTCCATTATTTATTTGCTCTGCTCTCAGGAA
GCGACGTGACCCCTGCCCCAGCTGGAACCTGGCAGAGGCCTTAGGACCCCGTT
CCAAGTGCACCTGCCCGGCCAAGCCCCAGCCTCAGCCTGCGCCTGAGCTGCATG
CGCCACCATTTTTGGCAGCGTGGCAGCTTTGCAAGGGGCTGGGGCCCTCGGCGT
30 GGGGCCATGCCTTCTGTGTGTTCTGTAGTGTCTGGGATTTGCCGGTGCTCAATA
AATGTTTATTCATTGACGGTGAAAAAAAAAAAAAAAAAAAAA.

15. Nucleic acid, characterised in that it contains the sequence

ATGGCGGATTCCAGCGAAGGCCCGCGCGGGGCGGGGAGGTGGCTGAGCT
CCCCGGGGATGAGAGTGGCACCCAGGTGGGGAGGCTTTTCCTCTCTCCTCCCT
GGCCAATCTGTTTGAGGGGGAGGATGGCTCCCTTTCGCCCTCACCGGCTGATGC
CAGTCGCCCTGCTGGCCCAGGCGATGGGCGACCAAATCTGCGCATGAAGTTCC
5 AGGGCGCCTTCCGCAAGGGGGTGCCCAACCCCATCGATCTGCTGGAGTCCACC
CTATATGAGTCCTCGGTGGTGCCTGGGCCCAAGAAAGCACCCATGGACTCACT
GTTTGACTACGGCACCTATCGTCACCACTCCAGTGACAACAAGAGGTGGAGGA
AGAAGATCATAGAGAAGCAGCCGCAGAGCCCCAAAGCCCCTGCCCTCAGCCG
CCCCCATCCTCAAAGTCTTCAACCGGCCTATCCTCTTTGACATCGTGTCCCGG
10 GGCTCCACTGCTGACCTGGACGGGCTGCTCCCATTCTTGCTGACCCACAAGAAA
CGCCTAACTGATGAGGAGTTTCGAGAGCCATCTACGGGGAAGACCTGCCTGCC
CAAGGCCTTGCTGAACCTGAGCAATGGCCGCAACGACACCATCCCTGTGCTGCT
GGACATCGCGGAGCGCACCGGCAACATGCGGGAGTTCATTAACCTCGCCCTTCC
GTGACATCTACTATCGAGGTCAGACAGCCCTGCACATCGCCATTGAGCGTCGCT
15 GCAAACACTACGTGGAACCTTCTCGTGGCCCAGGGAGCTGATGTCCA₆GCCCAGG
CCCGTGGGCGCTTCTTCCAGCCCAAGGATGAGGGGGGCTACTTCTACTTTGGGG
AGCTGCCCCTGTCGCTGGCTGCCTGCACCAACCAGCCCCACATTGTCAACTACC
TGACGGAGAACCCCCACAAGAAGGCGGACATGCGGCGCCAGGACTCGCGAGG
CAACACAGTGCTGCATGCGCTGGTGGCCATTGCTGACAACACCCGTGAGAACA
20 CCAAGTTTGTTACCAAGATGTACGACCTGCTGCTGCTCAAGTGTGCCCGCCTCT
TCCCCGACAGCAACCTGGAGGCCGTGCTCAACAACGACGGCCTCTCGCCCCTC
ATGATGGCTGCCAAGACGGGCAAGATTGGGATCTTTCAGCACATCATCCGGCG
GGAGGTGACGGATGAGGACACACGGCACCTGTCCCGCAAGTTCAAGGACTGGG
CCTATGGGCCAGTGTATTCTTCGCTTTATGACCTCTCCTCCCTGGACACGTGTGG
25 GGAAGAGGCCTCCGTGCTGGAGATCCTGGTGTACAACAGCAAGATTGAGAACC
GCCACGAGATGCTGGCTGTGGAGCCCATCAATGAACTGCTGCGGGACAAGTGG
CGCAAGTTCGGGGCCGTCTCCTTCTACATCAACGTGGTCTCCTACCTGTGTGCC
ATGGTCATCTTCACTCTCACCGCCTACTACCAGCCGCTGGAGGGCACACCGCCG
TACCCTTACCGCACCACGGTGGACTACCTGCGGCTGGCTGGCGAGGTGATTACG
30 CTCTTCACTGGGGTCCTGTTCTTCTTACCAACATCAAAGACTTGTTTCATGAAG
AAATGCCCTGGAGTGAATTCTCTTTCATTGATGGCTCCTTCCAGCTGCTCTACT
TCATCTACTCTGTCTGGTGATCGTCTCAGCAGCCCTCTACCTGGCAGGGATCG
AGGCCTACCTGGCCGTGATGGTCTTTGCCCTGGTCCTGGGCTGGATGAATGCCC
TTTACTTCACCCGTGGGCTGAAGCTGACGGGGACCTATAGCATCATGATCCAGA

AGATTCTCTTCAAGGACCTTTTCCGATTCTGCTCGTCTACTTGCTCTTCATGAT
CGGCTACGCTTCAGCCCTGGTCTCCCTCCTGAACCCGTGTGCCAACATGAAGGT
GTGCAATGAGGACCAGACCAACTGCACAGTGCCCACTTACCCCTCGTGCCGTG
ACAGCGAGACCTTCAGCACCTTCCTCCTGGACCTGTTTAAGCTGACCATCGGCA
5 TGGGCGACCTGGAGATGCTGAGCAGCACCAAGTACCCCGTGGTCTTCATCATCC
TGCTGGTGACCTACATCATCCTCACCTTTGTGCTGCTCCTCAACATGCTCATTGC
CCTCATGGGCGAGACAGTGGGCCAGGTCTCCAAGGAGAGCAAGCACATCTGGA
AGCTGCAGTGGGCCACCACCATCCTGGACATTGAGCGCTCCTTCCCCGTATTCC
TGAGGAAGGCCTTCCGCTCTGGGGAGATGGTCACCGTGGGCAAGAGCTCGGAC
10 GGCACTCCTGACCGCAGGTGGTGCTTCAGGGTGGATGAGGTGAACTGGTCTCA
CTGGAACCAGAACTTGGGCATCATCAACGAGGACCCGGGCAAGAATGAGACCT
ACCACTATTATGGCTTCTCGCATACCGTGGGCCGCCTCCGCAGGGATCGCTGGT
CCTCGGTGGTACCCCGCGTGGTGGAAGTGAACAAGAACTCGAACCCGGACGAG
GTGGTGGTGCCTCTGGACAGCATGGGGAACCCCGCTGCGATGGCCACCAGCA
15 GGGTTACCCCGCAAGTGGAGGACTGAGGACGCCCCGCTCTAG

or a partial sequence thereof, a nucleic acid which is capable of hybridising with
said sequence under stringent conditions, an allelic variant or a functional variant of
said sequence or a variant of nucleic acid on the basis of the degenerative code.

20 16. Nucleic acid, characterised in that it has the sequence

ATGGCGGATTCCAGCGAAGGCCCGCGCGGGGCGGGGAGGTGGCTGAGCT
CCCCGGGGATGAGAGTGGCACCCAGGTGGGGAGGCTTTTCCTCTCTCCTCCCT
GGCCAATCTGTTTGAGGGGGAGGATGGCTCCCTTTCGCCCTACCGGCTGATGC
CAGTCGCCCTGCTGGCCCAGGCGATGGGCGACCAAATCTGCGCATGAAGTTCC
25 AGGGCGCCTTCCGCAAGGGGGTGCCCAACCCCATCGATCTGCTGGAGTCCACC
CTATATGAGTCCTCGGTGGTGCTGGGCCCAAGAAAGCACCCATGGACTCACT
GTTTGACTACGGCACCTATCGTCACCACTCCAGTGACAACAAGAGGTGGAGGA
AGAAGATCATAGAGAAGCAGCCGCAGAGCCCCAAAGCCCCTGCCCCTCAGCCG
CCCCCATCCTCAAAGTCTTCAACCGGCCTATCCTCTTTGACATCGTGTCCCGG
30 GGCTCCACTGCTGACCTGGACGGGCTGCTCCCATTTCTTGCTGACCCACAAGAAA
CGCCTAACTGATGAGGAGTTTCGAGAGCCATCTACGGGGAAGACCTGCCTGCC
CAAGGCCTTGCTGAACCTGAGCAATGGCCGCAACGACACCATCCCTGTGCTGCT
GGACATCGCGGAGCGCACCGGCAACATGCGGGAGTTCATTAAGTCCGCCCTTCC
GTGACATCTACTATCGAGGTCAGACAGCCCTGCACATCGCCATTGAGCGTCCGCT

GCAAACACTACGTGGAACCTTCTCGTGGCCCAGGGAGCTGATGTCCA;GCCCAGG
CCCGTGGGCGCTTCTTCCAGCCCAAGGATGAGGGGGGCTACTTCTACTTTGGGG
AGCTGCCCCCTGTCGCTGGCTGCCTGCACCAACCAGCCCCACATTGTCAACTACC
TGACGGAGAACCCCCACAAGAAGGCGGACATGCGGGCGCCAGGACTCGCGAGG
5 CAACACAGTGCTGCATGCGCTGGTGGCCATTGCTGACAACACCCGTGAGAACA
CCAAGTTTGTACCAAGATGTACGACCTGCTGCTGCTCAAGTGTGCCCCGCCTCT
TCCCCGACAGCAACCTGGAGGCCGTGCTCAACAACGACGGCCTCTCGCCCCCTC
ATGATGGCTGCCAAGACGGGCAAGATTGGGATCTTTCAGCACATCATCCGGCG
GGAGGTGACGGATGAGGACACACGGCACCTGTCCCGCAAGTTCAAGGACTGGG
10 CCTATGGGCCAGTGTATTCTCGCTTTATGACCTCTCCTCCCTGGACACGTGTGG
GGAAGAGGCCTCCGTGCTGGAGATCCTGGTGTACAACAGCAAGATTGAGAACC
GCCACGAGATGCTGGCTGTGGAGCCCATCAATGAACTGCTGCGGGACAAGTGG
CGCAAGTTCGGGGCCGTCTCCTTCTACATCAACGTGGTCTCCTACCTGTGTGCC
ATGGTCATCTTCACTCTCACCGCCTACTACCAGCCGCTGGAGGGCACACCGCCC
15 TACCCTTACCGCACCACGGTGGACTACCTGCGGCTGGCTGGCGAGGTCATTACG
CTCTTCACTGGGGTCCTGTTCTTCTTACCAACATCAAAGACTTGTTTCATGAAG
AAATGCCCTGGAGTGAATTCTCTTTCATTGATGGCTCCTTCCAGCTGCTCTACT
TCATCTACTCTGTCTGGTGATCGTCTCAGCAGCCCTCTACCTGGCAGGGATCG
AGGCCTACCTGGCCGTGATGGTCTTTGCCCTGGTCCTGGGCTGGATGAATGCCC
20 TTTACTTCACCCGTGGGCTGAAGCTGACGGGGACCTATAGCATCATGATCCAGA
AGATTCTCTTCAAGGACCTTTTCCGATTCTGCTCGTCTACTTGCTCTTCATGAT
CGGCTACGCTTCAGCCCTGGTCTCCCTCCTGAACCCGTGTGCCAACATGAAGGT
GTGCAATGAGGACCAGACCAACTGCACAGTGCCCACTTACCCCTCGTGCCGTG
ACAGCGAGACCTTCAGCACCTTCCTCCTGGACCTGTTTAAGCTGACCATCGGCA
25 TGGGCGACCTGGAGATGCTGAGCAGCACCAAGTACCCCGTGGTCTTCATCATCC
TGCTGGTGACCTACATCATCCTCACCTTTGTGCTGCTCCTCAACATGCTCATTGC
CCTCATGGGCGAGACAGTGGGCCAGGTCTCCAAGGAGAGCAAGCACATCTGGA
AGCTGCAGTGGGCCACCACCATCCTGGACATTGAGCGCTCCTTCCCCGTATTCC
TGAGGAAGGCCTTCCGCTCTGGGGAGATGGTCAACGTGGGCAAGAGCTCGGAC
30 GGCACTCCTGACCGCAGGTGGTGCTTCAGGGTGGATGAGGTGAACTGGTCTCA
CTGGAACCAGAACTTGGGCATCATCAACGAGGACCCGGGCAAGAATGAGACCT
ACCAGTATTATGGCTTCTCGCATACCGTGGGCCGCCTCCGCAGGGATCGCTGGT
CCTCGGTGGTACCCCGCGTGGTGGAACTGAACAAGAACTCGAACCCGGACGAG

GTGGTGGTGCCTCTGGACAGCATGGGGAACCCCCGCTGCGATGGCCACCAGCA
GGGTTACCCCCGCAAGTGGAGGACTGAGGACGCCCCGCTCTAG.

17. Nucleic acid, characterised in that it comprises the sequence

5 GGCCACGCGTCGACTAGTACGGGGGGGGGGGGGGGGGGTGGCRGSRGGAKCAG
GACTCGGCCGGAGGGATCAGGAAGCGGCGGCGCTGCGCCCCGCGTCCTGAGGCT
GAGAAGTACAAACAGATCTGGGTCCAGTATGGCAGATCCTGGTGATGGTCCCC
GTGCAGCGCCTGGGGAGGTGGCTGAGCCCCCTGGAGATGAGAGTGGTACCTCT
GGTGGGGAGGCCTTCCCCCTCTCTTCCCTGGCCAATCTGTTTGAGGGGGAGGAA
10 GGCTCCTCTTCTCTTCCCCGGTGGATGCTAGCCGCCCTGCTGGCCCTGGCGAT
GGACGTCCAAACCTGCGTATGAAGTTCCAGGGCGCTTTCGCAAGGGGGTTCC
CAACCCCATTTGACCTGTTGGAGTCCACCCGGTACGAGTCCTCAGTAGTGCCTGG
GCCAAGAAAGCGCCCATGGATTCTTGTTCGACTACGGCACTTACCGTCACCA
CCCCAGTGACAACAAGAGATGGAGGAGAAAGGTCGTGGAGAAGCAGCCACAG
15 AGCCCCAAAGCTCCTGCACCCCAGCCACCCCCCATCCTCAAAGTCTTCAATCGG
CCCATCCTCTTTGACATTGTGTCCCGGGGCTCCACTGCGGACCTAGATGGACTG
CTCTCCTTCTTGTGACCCACAAGAAGCGCCTGACTGATGAGGAGTTCCGGGAG
CCGTCCACGGGGAAGACCTGCCTGCCAAGGCGCTGCTGAACCTAAGCAACGG
GCGCAACGACACCATCCCGGTGTTGCTGGACATTGCGGAGCGCACCGGCAACA
20 TGCGTGAATTCATCAACTCGCCCTTCAGAGACATCTACTACCGAGGCCAGACAT
CCCTGCACATTGCCATCGAACGGCGCTGCAAGCACTACGTGGAGCTGCTGGTG
GCCAGGGAGCCGACGTGCACGCCAGGCCCGCGGCCGCTTCTTCCAGCCCCAA
GGATGAGGGAGGCTACTTCTACTTTGGGGAGCTGCCCTTGTCCCTGGCAGCCTG
CACCAACCAGCCGCACATCGTCAACTACCTGACAGAGAACCCTCACAAGAAAG
25 CTGACATGAGGCGACAGGACTCGAGGGGGGAACACGGTGCTGCACGCGCTGGTG
GCCATCGCCGACAACACCCGAGAGAACACCAAGTTTGTACCAAGATGTACGA
CCTGCTGCTTCTCAAGTGTTACGCCTCTTCCCCGACAGCAACCTGGAGACAGT
TCTCAACAATGATGGCCTTTCGCCTCTCATGATGGCTGCCAAGACAGGCAAGAT
CGGGGTCTTTCAGCACATCATCCGACGTGAGGTGACAGATGAGGACACCCGGC
30 ATCTGTCTCGCAAGTTCAAGGACTGGGCCTATGGGCCTGTGTATTCTTCTCTCTA
CGACCTCTCCTCCCTGGACACATGCGGGGAGGAGGTGTCCGTGCTGGAGATCCT
GGTGTAACAACAGCAAGATCGAGAACCGCCATGAGATGCTGGCTGTAGAGCCCA
TTAACGAAGTGTGAGAGACAAGTGGCGTAAGTTTGGGGCTGTGTCCTTCTACA
TCAACGTGGTCTCCTATCTGTGTGCCATGGTCATCTTACCCTCACCGCCTACTA

[illegible]

or a partial sequence thereof, a nucleic acid which is capable of hybridising with said sequence under stringent conditions, an allelic variant or a functional variant of said sequence or a variant of the nucleic acid on the basis of the degenerative code, wherein R may be an A or G, M may be an A or C, S may be a C or G, Y may be a C or T, K may be a G or T and W may be an A or T.

18. Nucleic acid, characterised in that it has the sequence

GGCCACGCGTCGACTAGTACGGGGGGGGGGGGGGGGGGTGGCRGSRGGAKCAG
GACTCGGCCGGAGGGATCAGGAAGCGGCGGCGCTGCGCCCGCGTCCTGAGGCT
10 GAGAAGTACAAACAGATCTGGGTCCAGTATGGCAGATCCTGGTGTATGGTCCCC
GTGCAGCGCCTGGGGAGGTGGCTGAGCCCCCTGGAGATGAGAGTGGTACCTCT
GGTGGGGAGGCCTTCCCCCTCTCTTCCCTGGCCAATCTGTTTGAGGGGGAGGAA
GGCTCCTCTTCTCTTTCCCCGGTGGATGCTAGCCGCCCTGCTGGCCCTGGCGAT
GGACGTCCAAACCTGCGTATGAAGTTCCAGGGCGCTTTCCGCAAGGGGGTTCC
15 CAACCCCATTTGACCTGTTGGAGTCCACCCGGTACGAGTCCTCAGTAGTGCCTGG
GCCCAAGAAAGCGCCCATGGATTCTTGTTCGACTACGGCACTTACCGTCACCA
CCCCAGTGACAACAAGAGATGGAGGAGAAAGGTCGTGGAGAAGCAGCCACAG
AGCCCCAAAGCTCCTGCACCCCAGCCACCCCCCATCCTCAAAGTCTTCAATCGG
CCCATCCTCTTTGACATTGTGTCCCGGGGCTCCACTGCGGACCTAGATGGACTG
20 CTCTCCTTCTTGTGACCCACAAGAAGCGCCTGACTGATGAGGAGTTCCGGGAG
CCGTCCACGGGGAAGACCTGCCTGCCCAAGGCGCTGCTGAACCTAAGCAACGG
GCGCAACGACACCATCCCGGTGTTGCTGGACATTGCGGAGCGCACCGGCAACA
TGCGTGAATTCATCAACTCGCCCTTCAGAGACATCTACTACCGAGGCCAGACAT
CCCTGCACATTGCCATCGAACGGCGCTGCAAGCACTACGTGGAGCTGCTGGTG
25 GCCCAGGGAGCCGACGTGCACGCCAGGCCCGCGGCCGCTTCTTCCAGCCCAA
GGATGAGGGGAGGCTACTTCTACTTTGGGGAGCTGCCCTTGTCCCTGGCAGCCTG
CACCAACCAGCCGCACATCGTCAACTACCTGACAGAGAACCCTCACAAGAAAG
CTGACATGAGGCGACAGGACTCGAGGGGGGAACACGGTGCTGCACGCGCTGGTG
GCCATCGCCGACAACACCCGAGAGAACACCAAGTTTGTACCAAGATGTACGA
30 CCTGCTGCTTCTCAAGTGTTACGCCTCTTCCCCGACAGCAACCTGGAGACAGT
TCTCAACAATGATGGCCTTTCGCCTCTCATGATGGCTGCCAAGACAGGCAAGAT
CGGGGTCTTTCAGCACATCATCCGACGTGAGGTGACAGATGAGGACACCCGGC
ATCTGTCTCGCAAGTTCAAGGACTGGGCCTATGGGCCTGTGTATTCTTCTCTCTA
CGACCTCTCCTCCCTGGACACATGCGGGGAGGAGGTGTCCGTGCTGGAGATCCT

GGTGTACAACAGCAAGATCGAGAACCGCCATGAGATGCTGGCTGTAGAGCCCA
TTAACGAACTGTTGAGAGACAAGTGGCGTAAGTTTGGGGCTGTGTCCTTCTACA
TCAACGTGGTCTCCTATCTGTGTGCCATGGTCATCTTCACCCTCACCGCCTACTA
TCAGCCACTGGAGGGCACGCCACCCTACCCTTACCGGACCACAGTGGACTACC
5 TGAGGCTGGCTGGCGAGGTCATCACGCTCTTCACAGGAGTCCTGTTCTTCTTTA
CCAGTATCAAAGACTTGTTACGAAGAAATGCCCTGGAGTGAATTCTCTCTTCG
TCGATGGCTCCTTCCAGTTACTCTACTTCATCTACTCTGTGCTGGTGGTGTCTC
TGCGGCGCTCTACCTGGCTGGGATCGAGGCCTACCTGGCTGTGATGGTCTTTGC
CCTGGTCCTGGGCTGGATGAATGCGCTGTACTTCACGCGCGGGTTGAAGCTGAC
10 GGGGACCTACAGCATCATGATTCAGAAGATCCTCTTCAAAGACCTCTTCCGCTT
CCTGCTTGTGTACCTGCTCTTCATGATCGGCTATGCCTCAGCCCTGGTCACCCTC
CTGAATCCGTGCACCAACATGAAGGTCTGTGACGAGGACCAGAGCAACTGCAC
GGTGCCACGTATCCTGCGTGCCGCGACAGCGAGACCTTCAGCGCCTTCCTCCT
GGACCTCTTCAAGCTCACCATCGGCATGGGAGACCTGGAGATGCTGAGCAGCG
15 CCAAGTACCCCGTGGTCTTCATCCTCCTGCTGGTCACCTACATCATCCTCACCTT
CGTGCTCCTGTTGAACATGCTTATCGCCCTCATGGGTGAGACCGTGGGCCAGGT
GTCCAAGGAGAGCAAGCACATCTGGAAGTTGCAGTGGGCCACCACCATCCTGG
ACATCGAGCGTTCCTTCCCTGTGTTCTGAGGAAGGCCTTCCGCTCCGGAGAGA
TGGTGACTGTGGGCAAGAGCTCAGATGGCACTCCGGACCGCAGGTGGTGCTTC
20 AGGGTGGACGAGGTGAACTGGTCTCACTGGAACCAGAACTTGGGCATCATTA
CGAGGACCCTGGCAAGAGTGAAATCTACCAGTACTATGGCTTCTCCACACCGT
GGGGCGCCTTCGTAGGGATCGTTGGTCCTCGGTGGTGCCCCGCGTAGTGGAGCT
GAACAAGAACTCAAGCGCAGATGAAGTGGTGGTACCCCTGGATAACCTAGGGA
ACCCCAACTGTGACGGCCACCAGCAGGGCTACGCTCCCAAGTGGAGGACGGAC
25 GATGCCCCACTGTAGGGGCCGTGCCAGAGCTCGCACAGATAGTCCAGGCTTGG
CCTTCGCTCCACCTACATTTAGGCATTTGTCCGGTGTCTTCCACACCCGCATG
GGACCTTGGAGGTGAGGGCCTCTGTGGCGACTCTGTGGAGGCCCCAGGACCCT
CTGGTCCCCGCCAAGACTTTTGCCTTCAGCTCTACTCCCCACATGGGGGGGCGG
GGCTCCTGGCTACCTGTCTCGCTCGCTCCCATGGAGTCACCTAAGCCAGCACAA
30 GGCCCCCTCCTCGAAAGGCTCAGGCCCCATCCCTCTTGTGTATTATTTATTGCT
CTCCTCAGGAAAATGGGGTGGCAGGAGTCCACCCGCGGCTGGAACCTGGCCAG
GGCTGAAGCTCATGCAGGGACGCTGCAGCTCCGACCTGCCACAGATCTGACCT
GCTGCAGCCCTGGCTAGTGTGGGTCTTCTGTACTTTGAAGAGATCGGGGCCGCT
GGTGCTCAATAAATGTTTATTCTCGGTGGAAAAAAAAAAAAAAAAAAAAAAAAA

AA
AA,

wherein R may be an A or G, M may be an A or C, S may be a C or G, Y may be a
C or T, K may be a G or T and W may be an A or T.

5

19. Nucleic acid, characterised in that it contains the sequence

ATGGCAGATCCTGGTGATGGTCCCCGTGCAGCGCCTGGGGAGGTGGCTGAGCC
CCCTGGAGATGAGAGTGGTACCTCTGGTGGGGAGGCCTTCCCCCTCTCTTCCCT
GGCCAATCTGTTTGAGGGGGAGGAAGGCTCCTCTTCTCTTTCCCCGGTGATGC
10 TAGCCGCCCTGCTGGCCCTGGCGATGGACGTCCAAACCTGCGTATGAAGTTCCA
GGGCGCTTTCCGCAAGGGGGTTCCCAACCCCATTGACCTGTTGGAGTCCACCCG
GTACGAGTCCTCAGTAGTGCCTGGGCCCAAGAAAGCGCCCATGGATTCTTGT
CGACTACGGCACTTACCGTCACCACCCAGTGACAACAAGAGATGGAGGAGAA
AGGTCGTGGAGAAGCAGCCACAGAGCCCCAAAGCTCCTGCACCCAGCCACCC
15 CCCATCCTCAAAGTCTTCAATCGGCCCATCCTCTTTGACATTGTGTCCCGGGGCT
CCACTGCGGACCTAGATGGACTGCTCTCCTTCTTGTGACCCACAAGAAGCGCC
TGACTGATGAGGAGTTCCGGGAGCCGTCCACGGGGAAGACCTGCCTGCCCAAG
GCGCTGCTGAACCTAAGCAACGGGCGCAACGACACCATCCCGGTGTTGCTGGA
CATTGCGGAGCGCACCGGCAACATGCGTGAATTCATCAACTCGCCCTTCAGAG
20 ACATCTACTACCGAGGCCAGACATCCCTGCACATTGCCATCGAACGGCGCTGC
AAGCACTACGTGGAGCTGCTGGTGGCCCAGGGAGCCGACGTGCACGCCAGGC
CCGCGGCCGCTTCTTCCAGCCCAAGGATGAGGGAGGCTACTTCTACTTTGGGGA
GCTGCCCTTGTCCCTGGCAGCCTGCACCAACCAGCCGCACATCGTCAACTACCT
GACAGAGAACCCTCACAAGAAAGCTGACATGAGGCGACAGGACTCGAGGGGG
25 AACACGGTGCTGCACGCGCTGGTGGCCATCGCCGACAACACCCGAGAGAACAC
CAAGTTTGTACCAAGATGTACGACCTGCTGCTTCTCAAGTGTTACGCCTCTT
CCCCGACAGCAACCTGGAGACAGTTCTCAACAATGATGGCCTTTCGCCTCTCAT
GATGGCTGCCAAGACAGGCAAGATCGGGGTCTTTCAGCACATCATCCGACGTG
AGGTGACAGATGAGGACACCCGGCATCTGTCTCGCAAGTTCAAGGACTGGGCC
30 TATGGGCCTGTGTATTCTTCTCTACGACCTCTCCTCCCTGGACACATGCGGGG
AGGAGGTGTCCGTGCTGGAGATCCTGGTGTACAACAGCAAGATCGAGAACCGC
CATGAGATGCTGGCTGTAGAGCCCATTAACGAACTGTTGAGAGACAAGTGGCG
TAAGTTTGGGGCTGTGTCCTTCTACATCAACGTGGTCTCCTATCTGTGTGCCATG
GTCATCTTCACCCTCACCGCCTACTATCAGCCACTGGAGGGCACGCCACCCTAC

CCTTACCGGACCACAGTGGACTACCTGAGGCTGGCTGGCGAGGTCATCACGCT
CTTCACAGGAGTCCTGTTCTTCTTTACCAGTATCAAAGACTTGTTACGAAGAA
ATGCCCTGGAGTGAATTCTCTCTTCGTCGATGGCTCCTTCCAGTTACTCTACTTC
ATCTACTCTGTGCTGGTGGTTGTCTCTGCGGCGCTCTACCTGGCTGGGATCGAG
5 GCCTACCTGGCTGTGATGGTCTTTGCCCTGGTCCTGGGCTGGATGAATGCGCTG
TACTTCACGCGCGGGTTGAAGCTGACGGGGACCTACAGCATCATGATTCAGAA
GATCCTCTTCAAAGACCTCTTCCGCTTCCTGCTTGTGTACCTGCTCTTCATGATC
GGCTATGCCTCAGCCCTGGTCACCCTCCTGAATCCGTGCACCAACATGAAGGTC
TGTGACGAGGACCAGAGCAACTGCACGGTGCCACGTATCCTGCGTGCCGCGA
10 CAGCGAGACCTTCAGCGCCTTCCTCCTGGACCTCTTCAAGCTCACCATCGGCAT
GGGAGACCTGGAGATGCTGAGCAGCGCCAAGTACCCCGTGGTCTTCATCCTCCT
GCTGGTCACCTACATCATCCTCACCTTCGTGCTCCTGTTGAACATGCTTATCGCC
CTCATGGGTGAGACCGTGGGCCAGGTGTCCAAGGAGAGCAAGCACATCTGGAA
GTTGCAGTGGGCCACCACCATCCTGGACATCGAGCGTTCCTTCCCTGTGTTCT
15 GAGGAAGGCCTTCCGCTCCGGAGAGATGGTGACTGTGGGCAAGAGCTCAGATG
GCACTCCGGACCGCAGGTGGTGCTTCAGGGTGGACGAGGTGAACTGGTCTCAC
TGGAACCAGAACTTGGGCATCATTAAACGAGGACCCTGGCAAGAGTGAAATCTA
CCAGTACTATGGCTTCTCCACACCGTGGGGCGCCTTCGTAGGGATCGTTGGTC
CTCGGTGGTGCCCCGCGTAGTGGAGCTGAACAAGAACTCAAGCGCAGATGAAG
20 TGGTGGTACCCCTGGATAACCTAGGGAACCCCAACTGTGACGGCCACCAGCAG
GGCTACGCTCCCAAGTGGAGGACGGACGATGCCCCACTGTAG

or a partial sequence thereof, a nucleic acid which is capable of hybridising with
said sequence under stringent conditions, an allelic variant or a functional variant of
said sequence or a variant of the nucleic acid on the basis of the degenerative code.

25

20. Nucleic acid, characterised in that it has the sequence

ATGGCAGATCCTGGTGATGGTCCCCGTGCAGCGCCTGGGGAGGTGGCTGAGCC
CCCTGGAGATGAGAGTGGTACCTCTGGTGGGGAGGCCTTCCCCCTCTCTTCCCT
GGCCAATCTGTTTGAGGGGGAGGAAGGCTCCTCTTCTTTCCCCGGTGGATGC
30 TAGCCGCCCTGCTGGCCCTGGCGATGGACGTCCAAACCTGCGTATGAAGTTCCA
GGGCGCTTTCGCAAGGGGGTTCCCAACCCCATTTGACCTGTTGGAGTCCACCCG
GTACGAGTCCTCAGTAGTGCCTGGGCCCAAGAAAGCGCCCATGGATTCTTGT
CGACTACGGCACTTACCGTCACCACCCAGTGACAACAAGAGATGGAGGAGAA
AGGTCGTGGAGAAGCAGCCACAGAGCCCCAAAGCTCCTGCACCCAGCCACCC

CCCATCCTCAAAGTCTTCAATCGGCCCATCCTCTTTGACATTGTGTCCCGGGGCT
CCTACTGCGGACCTAGATGGACTGCTCTCCTTCTTGTTGACCCACAAGAAGCGCC
TGACTGATGAGGAGTTCCGGGAGCCGTCCACGGGGAAGACCTGCCTGCCCAAG
GCGCTGCTGAACCTAAGCAACGGGCGCAACGACACCATCCCGGTGTTGCTGGA
5 CATTGCGGAGCGCACCGGCAACATGCGTGAATTCATCAACTCGCCCTTCAGAG
ACATCTACTACCGAGGCCAGACATCCCTGCACATTGCCATCGAACGGGCGCTGC
AAGCACTACGTGGAGCTGCTGGTGGCCCAGGGAGCCGACGTGCACGCCCAGGC
CCGCGGCCGCTTCTTCCAGCCCAAGGATGAGGGAGGCTACTTCTACTTTGGGGA
GCTGCCCTTGTCCTGGCAGCCTGCACCAACCAGCCGCACATCGTCAACTACCT
10 GACAGAGAACCCTCACAAGAAAGCTGACATGAGGCGACAGGACTCGAGGGGG
AACACGGTGCTGCACGCGCTGGTGGCCATCGCCGACAACACCCGAGAGAACAC
CAAGTTTGTACCAAGATGTACGACCTGCTGCTTCTCAAGTGTTACGCCTCTT
CCCCGACAGCAACCTGGAGACAGTTCTCAACAATGATGGCCTTTCGCCTCTCAT
GATGGCTGCCAAGACAGGCAAGATCGGGGTCTTTCAGCACATCATCCGACGTG
15 AGGTGACAGATGAGGACACCCGGCATCTGTCTCGCAAGTTCAAGGACTGGGCC
TATGGGCCTGTGTATTCTTCTCTCTACGACCTCTCCTCCCTGGACACATGCGGGG
AGGAGGTGTCCGTGCTGGAGATCCTGGTGTACAACAGCAAGATCGAGAACCGC
CATGAGATGCTGGCTGTAGAGCCCATTAACGAACTGTTGAGAGACAAGTGGCG
TAAGTTTGGGGCTGTGTCCTTCTACATCAACGTGGTCTCCTATCTGTGTGCCATG
20 GTCATCTTCAACCCTCACCGCCTACTATCAGCCACTGGAGGGCACGCCACCCTAC
CCTTACCGGACCACAGTGGACTACCTGAGGCTGGCTGGCGAGGTCATCACGCT
CTTACAGGAGTCCTGTTCTTCTTTACCAGTATCAAAGACTTGTTACGAAGAA
ATGCCCTGGAGTGAATTCTCTCTTCGTCGATGGCTCCTTCCAGTTACTCTACTTC
ATCTACTCTGTGCTGGTGGTTGTCTCTGCGGCGCTCTACCTGGCTGGGATCGAG
25 GCCTACCTGGCTGTGATGGTCTTTGCCCTGGTCCTGGGCTGGATGAATGCGCTG
TACTTCACGCGCGGGTTGAAGCTGACGGGGACCTACAGCATCATGATTCAGAA
GATCCTCTTCAAAGACCTCTTCCGCTTCCTGCTTGTGTACCTGCTCTTCATGATC
GGCTATGCCTCAGCCCTGGTCACCCTCCTGAATCCGTGCACCAACATGAAGGTC
TGTGACGAGGACCAGAGCAACTGCACGGTGCCACGTATCCTGCGTGCCGCGA
30 CAGCGAGACCTTCAGCGCCTTCCCTCCTGGACCTCTTCAAGCTCACCATCGGCAT
GGGAGACCTGGAGATGCTGAGCAGCGCCAAGTACCCCGTGGTCTTCATCCTCCT
GCTGGTCACCTACATCATCCTCACCTTCGTGCTCCTGTTGAACATGCTTATCGCC
CTCATGGGTGAGACCGTGGGCCAGGTGTCCAAGGAGAGCAAGCACATCTGGAA
GTTGCAGTGGGCCACCACCATCCTGGACATCGAGCGTTCCTTCCCTGTGTTCT

GAGGAAGGCCTTCCGCTCCGGAGAGATGGTGACTGTGGGCAAGAGCTCAGATG
GCACTCCGGACCGCAGGTGGTGCTTCAGGGTGGACGAGGTGAACTGGTCTCAC
TGGAACCAGAACTTGGGCATCATTAACGAGGACCCTGGCAAGAGTGAAATCTA
CCAGTACTATGGCTTCTCCCACACCGTGGGGCGCCTTCGTAGGGATCGTTGGTC
5 CTCGGTGGTGCCCCGCGTAGTGGAGCTGAACAAGAACTCAAGCGCAGATGAAG
TGGTGGTACCCCTGGATAACCTAGGGAACCCCAACTGTGACGGCCACCAGCAG
GGCTACGCTCCCAAGTGGAGGACGGACGATGCCCCACTGTAG.

21. Recombinant vector, characterised in that it contains a nucleic acid
10 according to one of claims 1 to 20.
22. Recombinant vector according to claim 21, characterised in that it is an
expression vector.
23. Host, characterised in that it contains a vector according to claim 21 or 22.
24. Host according to claim 23, characterised in that it is a eukaryotic host cell.
- 15 25. Host according to claim 23 or 24, characterised in that it is an insect cell.
26. Host according to one of claims 23 to 25, characterised in that it is an Sf9-,
HEK293- or HeLa-cell.
27. Host according to claim 23, characterised in that it is a bacteriophage.
28. Host according to claim 23, characterised in that it is a prokaryotic host cell.
- 20 29. Polypeptide, characterised in that it is coded by a nucleic acid according to
one of claims 1 to 20 or a fragment, a functional variant, an allelic variant, a
subunit, a variant on the basis of the degenerative nucleic acid code, a
chemical derivative thereof, a fusion protein with said polypeptide or a
glycosylation variant thereof.
- 25 30. Polypeptide according to claim 29, characterised in that it is a fragment of
the nonselective cation channel OTRPC4.
31. Polypeptide according to one of claims 29 and 30, characterised in that it is
a functional variant of the nonselective cation channel OTRPC4.
32. Polypeptide according to one of claims 29 to 31, characterised in that it is an
30 allelic variant of the nonselective cation channel OTRPC4.
33. Polypeptide according to one of claims 29 to 32, characterised in that it is a
subunit of the nonselective cation channel OTRPC4.

34. Polypeptide according to one of claims 29 to 33, characterised in that it is a variant of the nonselective cation channel OTRPC4 on the basis of the degenerative nucleic acid code.
35. Polypeptide according to one of claims 29 to 34, characterised in that it is a chemical derivative of the nonselective cation channel OTRPC4.
36. Polypeptide according to one of claims 29 to 35, characterised in that it is a fusion protein consisting of the nonselective cation channel OTRPC4 and another protein.
37. Polypeptide according to one of claims 29 to 36, characterised in that it is a glycosylation variant of the nonselective cation channel OTRPC4.
38. Process for preparing polypeptides according to one of claims 29 to 37, characterised in that a host according to one of claims 23 to 28 is cultivated and said polypeptide is isolated.
39. Antibody protein, characterised in that it is specific for a polypeptide according to one of claims 29 to 37.
40. Process for preparing an antibody protein according to claim 39, characterised in that it comprises the following steps: a host selected from a eukaryotic or prokaryotic cell which contains one or more vectors having one or more nucleic acids specific for the antibody protein, is cultivated under conditions under which said antibody protein is expressed by said host cell and said antibody protein is isolated.
41. Use of a polypeptide according to one of claims 29 to 37 for finding blockers, activators or modulators of said polypeptides.
42. Use of a host according to one of claims 23 to 28 for finding blockers, activators or modulators of OTRPC4 channels.
43. Process for finding blockers, activators or modulators of OTRPC4, characterised in that a host according to one of claims 23 to 28 is incubated with a test substance.
44. Process according to claim 43, characterised in that a membrane current is measured, said membrane current is compared with a membrane current which is measured in said host after incubation with a known control substance or in the absence of the test substance.

45. Process according to one of claims 43 and 44, characterised in that said blocker is bound to a channel, said host is incubated with a test substance and the displacement of the blocker or activator bound to the channel by the test substance is measured.
- 5 46. Process according to one of claims 43 to 45, characterised in that a host according to one of claims 23 to 28 is incubated with a test substance, the intracellular quantity of a divalent cation is determined and said quantity of divalent cation is compared with the quantity of said divalent cation which is measured when said host is incubated with a known control or in the
10 absence of the test substance.
47. Process according to one of claims 43 to 46, characterised in that said process is a high throughput screening (HTS) test or an ultrahigh throughput screening (UHTS) test.
48. Activator of OTRPC4 which can be found using a process according to
15 claims 43 to 47.
49. Blocker of OTRPC4 which can be found using a process according to claims 43 to 47.
50. Modulator of OTRPC4 which can be found using a process according to claims 43 to 47.
- 20 51. Antisense nucleic acid, characterised in that it is capable of hybridising with part of a nucleic acid according to one of claims 1 to 20 under stringent conditions.
52. Antisense nucleic acid according to claim 51, characterised in that it is a ribozyme.
- 25 53. Pharmaceutical composition, characterised in that it contains a nucleic acid according to one of claims 1 to 20 together with pharmaceutically acceptable carriers or excipients.
54. Pharmaceutical composition, characterised in that it contains an antisense nucleic acid according to one of claims 51 to 52 together with
30 pharmaceutically acceptable carriers or excipients .

55. Pharmaceutical composition, characterised in that it contains a polypeptide according to one of claims 29 to 37 together with pharmaceutically acceptable carriers or excipients.
56. Pharmaceutical composition, characterised in that it contains a vector according to one of claims 21 to 22 together with pharmaceutically acceptable carriers or excipients.
57. Pharmaceutical composition, characterised in that it contains a host according to one of claims 23 to 28 together with pharmaceutically acceptable carriers or excipients.
58. Use of a nucleic acid according to one of claims 1 to 20 for preparing a medicament for the treatment of a disease selected from among diabetes, hyperlipidaemia, hyperproteinaemia, hypertension, stroke, renal insufficiency, shock and other pathophysiological conditions characterised by hyper- and hypoosmolarity.
59. Use of an antisense nucleic acid according to one of claims 51 to 52 for preparing a medicament for the treatment of a disease selected from among diabetes, hyperlipidaemia, hyperproteinaemia, hypertension, stroke, renal insufficiency, shock and other pathophysiological conditions characterised by hyper- and hypoosmolarity.
60. Use of a vector according to one of claims 21 to 22 for preparing a medicament for the treatment of a disease selected from among diabetes, hyperlipidaemia, hyperproteinaemia, hypertension, stroke, renal insufficiency, shock and other pathophysiological conditions characterised by hyper- and hypoosmolarity.
61. Use of a host according to one of claims 23 to 28 for preparing a medicament for the treatment of a disease selected from among diabetes, hyperlipidaemia, hyperproteinaemia, hypertension, stroke, renal insufficiency, shock and other pathophysiological conditions characterised by hyper- and hypoosmolarity.
62. Non-human mammal, characterised in that, in addition to its genome, it contains a nucleic acid according to one of claims 1 to 20 (transgene).

63. Non-human mammal, characterised in that, in its genome, a nucleic acid according to one of claims 1 to 20 is inactivated (gene knock-out).
64. Non-human mammal, characterised in that, in its genome, a nucleic acid according to one of claims 1 to 20 is modified (gene knock-in).
- 5 65. Process for producing a non-human mammal, characterised in that
- a) embryonic stem cells of said non-human mammal are transfected with a vector which contains a nucleic acid according to one of claims 1 to 20 and permits recombination between the genomic DNA of said non-human mammal and the nucleic acid contained in the vector
 - 10 b) stably transfected stem cells from step a) are isolated and these are transferred into the germline of a female animal of said non-human mammal
 - c) the offspring of said female animal from step b) with a male animal of the same species are analysed for animals which express the polypeptide
 - 15 coded by the nucleic acid from step a).
66. Process for producing a non-human mammal, characterised in that
- d) embryonic stem cells of said non-human mammal are transfected with a vector which contains a nucleic acid which is capable of hybridising
 - 20 with a nucleic acid according to one of claims 1 to 20 under stringent conditions and is inactivated by insertion of an additional nucleic acid sequence and permits recombination between the genomic DNA of said non-human mammal and the nucleic acid contained in the vector
 - e) stably transfected stem cells from step d) are isolated and these are transferred into the germline of a female animal of said non-human
 - 25 mammal
 - f) the offspring of said female animal from step e) with a male animal of the same species are analysed for animals which express the polypeptide coded by the nucleic acid from step d) only slightly or not at all.
- 30 67. Process for producing a non-human mammal, characterised in that
- g) embryonic stem cells of said non-human mammal are transfected with a vector which contains a nucleic acid which is capable of hybridising

with a nucleic acid according to one of claims 1 to 20 under stringent conditions and is modified by insertion of an additional nucleic acid sequence and permits recombination between the genomic DNA of said non-human mammal and the nucleic acid contained in the vector

- 5 h) stably transfected stem cells from step g) are isolated and these are transferred into the germline of a female animal of said non-human mammal
- i) the offspring of said female animal from step h) with a male animal of the same species are analysed for animals which express the polypeptide
- 10 coded by the nucleic acid from step g).